Interestingly, disrupting the RSPO3-LGR4 interaction using an anti-RSPO3 antibody (rosmantuzumab) reduced the leukemia burden by promoting differentiation and impairing the self-renewal of stem cells in AML patient-derived xenografts without affecting normal hematopoietic stem cells. Here, LGR4 is linked to leukemia.